189 related articles for article (PubMed ID: 26229068)
1. A two-week regimen of high-dose integrase inhibitors does not cause nephrotoxicity in mice.
Eadon MT; Zhang H; Skaar TC; Hato T; Dagher PC; Gupta SK; Desta Z
Antivir Chem Chemother; 2015 Apr; 24(2):72-6. PubMed ID: 26229068
[TBL] [Abstract][Full Text] [Related]
2. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
Shah BM; Schafer JJ; Desimone JA
Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
[TBL] [Abstract][Full Text] [Related]
4. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits of using inulin clearance and cystatin C for determining glomerular filtration rate in HIV-1-infected individuals treated with dolutegravir.
Yukawa S; Watanabe D; Uehira T; Shirasaka T
J Infect Chemother; 2018 Mar; 24(3):199-205. PubMed ID: 29150412
[TBL] [Abstract][Full Text] [Related]
7. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
8. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
[TBL] [Abstract][Full Text] [Related]
10. The inhibition process of HIV-1 integrase by diketoacids molecules: Understanding the factors governing the better efficiency of dolutegravir.
El Khoury L; Piquemal JP; Fermandjian S; Maroun RG; Gresh N; Hobaika Z
Biochem Biophys Res Commun; 2017 Jul; 488(3):433-438. PubMed ID: 28478035
[TBL] [Abstract][Full Text] [Related]
11. [Safety profile of dolutegravir].
Rivero A; Domingo P
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():9-13. PubMed ID: 25858606
[TBL] [Abstract][Full Text] [Related]
12. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.
Pollicita M; Surdo M; Di Santo F; Cortese MF; Fabeni L; Fedele V; Malet I; Marcelin AG; Calvez V; Ceccherini-Silberstein F; Perno CF; Svicher V
J Antimicrob Chemother; 2014 Sep; 69(9):2412-9. PubMed ID: 24860155
[TBL] [Abstract][Full Text] [Related]
13. HIV pharmacotherapy: A review of integrase inhibitors.
Wong E; Trustman N; Yalong A
JAAPA; 2016 Feb; 29(2):36-40. PubMed ID: 26818644
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.
Osterholzer DA; Goldman M
Clin Infect Dis; 2014 Jul; 59(2):265-71. PubMed ID: 24723281
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.
Kandel CE; Walmsley SL
Drug Des Devel Ther; 2015; 9():3547-55. PubMed ID: 26185421
[TBL] [Abstract][Full Text] [Related]
16. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
17. Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways.
Zamek-Gliszczynski MJ; Zhang X; Mudunuru J; Du Y; Chen JL; Taskar KS; Huang J; Huang Y; Romach EH
Drug Metab Dispos; 2019 Aug; 47(8):890-898. PubMed ID: 31167838
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout.
Osman N; Mesplède T; Quashie PK; Oliveira M; Zanichelli V; Wainberg MA
J Antimicrob Chemother; 2015 Oct; 70(10):2810-5. PubMed ID: 26142476
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.
Cottrell ML; Hadzic T; Kashuba AD
Clin Pharmacokinet; 2013 Nov; 52(11):981-94. PubMed ID: 23824675
[TBL] [Abstract][Full Text] [Related]
20. Short Communication: The Clinical Value of Cystatin C as a Marker of Renal Function in HIV Patients Receiving Dolutegravir.
Yoshino Y; Koga I; Seo K; Kitazawa T; Ota Y
AIDS Res Hum Retroviruses; 2017 Nov; 33(11):1080-1082. PubMed ID: 28649847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
